Industry
Biotechnology
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
Loading...
Open
27.12
Mkt cap
1.9B
Volume
425K
High
27.75
P/E Ratio
-9.43
52-wk high
28.42
Low
26.75
Div yield
N/A
52-wk low
4.96
Portfolio Pulse from Benzinga Newsdesk
December 04, 2023 | 9:02 pm
Portfolio Pulse from Benzinga Newsdesk
November 02, 2023 | 5:53 pm
Portfolio Pulse from Benzinga Newsdesk
November 01, 2023 | 9:09 pm
Portfolio Pulse from Benzinga Neuro
October 18, 2023 | 1:52 am
Portfolio Pulse from Benzinga Insights
October 13, 2023 | 5:00 pm
Portfolio Pulse from Benzinga Newsdesk
October 13, 2023 | 1:45 pm
Portfolio Pulse from Benzinga Newsdesk
October 13, 2023 | 11:11 am
Portfolio Pulse from Benzinga Newsdesk
October 12, 2023 | 8:02 pm
Portfolio Pulse from Benzinga Newsdesk
September 08, 2023 | 10:57 am
Portfolio Pulse from Vandana Singh
September 07, 2023 | 6:12 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.